#genomics potential opportunity

[mariacallous]

Last August, KJ Muldoon was born with a potentially fatal genetic disorder. Just six months later, he received a Crispr treatment designed just for him.

Muldoon has a rare disorder known as CPS1 deficiency, which causes a dangerous amount of ammonia to build up in the blood. About half of babies born with it will die early in life. Current treatment options—a highly restrictive diet and liver transplantation—aren’t ideal. But a team at the Children’s Hospital of Philadelphia and Penn Medicine was able to bypass the standard years-long drug development timeline and use Cripsr to create a personalized medicine for KJ in a matter of months.

“We had a patient who was facing a very, very devastating outcome,” says Kiran Musunuru, professor for translational research at the University of Pennsylvania and Children’s Hospital of Philadelphia, who was part of the team that made KJ’s treatment.

When KJ was born, his muscles were rigid, he was lethargic, and he wouldn’t eat. After three doses of his custom treatment, KJ is starting to hit developmental milestones his parents never thought they’d see him reach. He’s now able to eat certain foods and sit upright by himself. “He really has made tremendous strides,” his father Kyle Muldoon says.

The case is detailed today in a study published in The New England Journal of Medicine and was presented at the American Society of Gene & Cell Therapy annual meeting in New Orleans. It could provide a blueprint for making customized gene-editing treatments for other patients with rare diseases that have few or no medical treatments available.

When the body digests protein, ammonia is made in the process. An important enzyme called CPS1 helps clear this toxic byproduct, but people with CPS1 deficiency lack this enzyme. Too much ammonia in the system can lead to organ damage, and even brain damage and death.

Since KJ’s birth, he has been on special ammonia-reducing medicines and a low-protein diet. After receiving the bespoke Crispr drug, though, KJ was able to go on a lower dose of the medication and start eating more protein without any serious side effects. He’s still in the hospital, but his doctors hope to send him home in the next month or so.

Both KJ’s parents and his medical team stop short of calling the Crispr therapy a cure, but they say it’s promising to see his improvement. “It's still very early, so we will need to continue to watch KJ closely to fully understand the full effects of this therapy,” says Rebecca Ahrens-Nicklas, director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at Children’s Hospital of Philadelphia and an assistant professor of pediatrics at Penn Medicine, who led the effort with Musunuru. She says the Crispr treatment probably turned KJ’s severe deficiency into a milder form of the disease, but he may still need to be on medication in the future.

Ahrens-Nicklas and Musunuru teamed up in 2023 to explore the feasibility of creating customized gene-editing therapies for individual patients. They decided to focus on urea cycle disorders, a group of genetic metabolic conditions that affect the body’s ability to process ammonia that includes CPS1 deficiency. Often, patients require a liver transplant. While the procedure is possible in infants, it’s medically complex. Ahrens-Nicklas and Musunuru saw an opportunity to find another path.

When KJ was born, the researchers used genome sequencing to determine the specific genetic mutation driving his disease. It turns out KJ had actually inherited two different mutations in the CPS1 gene—one from each parent. The team decided to target the mutation that had been reported before in an unrelated patient known to have severe CPS1 deficiency; the other hadn’t been seen before.

KJ’s team turned to Crispr, the Nobel Prize-winning technology that can precisely edit DNA. So far, only one Crispr-based medicine is commercially available. Approved in late 2023, it treats sickle cell disease and beta thalassemia. Other Crispr-based therapies are in development for more common diseases that affect tens or hundreds of thousands of patients.

The allure of Crispr is its potential to directly address the underlying genetic cause of a disease rather than simply treat symptoms, as the vast majority of current medicine does. The approved Crispr therapy, Casgevy, is given as a one-time treatment. But the Philadelphia-led team specifically designed KJ’s therapy to be redosable out of safety concerns, starting with a low dose to ensure there were no adverse effects. Terry Horgan, a 27-year-old with Duchenne muscular dystrophy, passed away in 2022 shortly after receiving the first known custom Crispr treatment. His death was likely due to a reaction to the virus used to deliver the Crispr molecules.

For KJ’s treatment, researchers used a version of Crispr called base editing that can change one “letter” in a DNA sequence to another. They packaged the base-editing components in tiny bubbles called lipid nanoparticles, which were then delivered via an IV infusion.

Before it could be given to KJ though, it was tested for safety in mice and monkeys. Since the drug was unapproved, the team needed permission from the Food and Drug Administration to use the experimental treatment in an individual patient. The researchers applied to the FDA on February 14 and received approval on February 21. They gave KJ his first dose on February 25.

“The clinical responses described are impressive,” says Timothy Yu, a neurologist at Boston Children’s Hospital who wasn’t involved in making KJ’s treatment. He says the Philadelphia team’s approach was a “very thoughtful and comprehensive end-to-end process.”

Yu’s lab has been working on customized genetic medicines based on antisense oligonucleotides, or ASOs—short molecules that block the production of proteins. Yu developed a personalized ASO in 10 months for a young girl with Batten disease, a rare and fatal neurodegenerative disorder. The treatment was dubbed milasen, after the patient, Mila. It was the first medicine that was tailor-made to treat a single patient’s genetic mutation. The treatment temporarily improved Mila’s condition and quality of life, but ultimately, she died in February 2021 at 10 years old.

“The superpower of Crispr base editing is its broad applicability to many types of genetic mutations. Its kryptonite is that we are in the very early days of demonstrating efficient and safe Crispr delivery to many different organs,” Yu says. ASOs, meanwhile, are well vetted for use in the brain, spinal cord, and eye, which are more difficult to address with Crispr.

Crispr could potentially address a variety of genetic diseases and types of cancer, but getting it to the right place in the body remains a challenge. The approved Crispr medicine, Casgevy, involves removing a patient’s cells and editing them outside the body, an arduous and expensive process. A drug given directly to the body would be much more practical. The liver is an easy first target because lipid nanoparticles naturally gravitate there, but only some diseases can be treated in this way.

Since urea cycle disorders primarily originate in the liver, they could be a prime target for custom Crispr medicines. “We’ve just written a new playbook,” says Fyodor Urnov, scientific director at the Innovative Genomics Institute at UC Berkeley, who collaborated on the paper.

Urnov says KJ’s case demonstrates that bespoke genetic treatments can be made quickly and used successfully to treat critically ill patients. “This could have failed in so many ways,” he says. “Nothing was a given.” Every day, he worried that KJ would pass away before they could finish making the therapy.

The team did not say exactly how much the therapy cost to produce, but Musunuru says it was comparable to the cost of a liver transplant, around $800,000. The companies involved in manufacturing—Aldevron, Danaher, and Integrated DNA Technologies—made in-kind contributions.

“Though it will take a lot of work to get there, my hope is that someday no rare disease patients will die prematurely from misspellings in their genes, because we'll be able to correct them,” Musunuru says.

[klauspeterrentrop]

Curious MedTech: Innovations Shaping Your Practice

Have you ever wondered how emerging medical technologies could transform your practice? In a world where technology evolves at a breathtaking pace, the latest breakthroughs in medical tech are not only fascinating but also have the potential to change the way healthcare is delivered forever. In this article, we explore four revolutionary areas—artificial intelligence, telemedicine, robotics, and genomics—that are stirring curiosity and reshaping clinical practices. With each breakthrough comes a world of possibilities that invite you to question, learn, and ultimately, integrate these advancements into your everyday practice.

Artificial Intelligence: Peering Into the Future of Diagnostics

Imagine a tool that can analyze mountains of medical data in seconds and spot patterns invisible to the naked eye. That’s the promise of artificial intelligence (AI) in healthcare—a field that continues to captivate researchers and practitioners alike. AI is redefining diagnostics by examining imaging scans, lab results, and patient histories with a level of precision that feels almost futuristic. Have you ever considered how an AI algorithm might detect the faintest hint of an anomaly in an MRI, potentially leading to an earlier diagnosis than ever before?

AI's role extends well beyond the realm of diagnostics. Picture a system that can sift through countless electronic health records, drawing connections between symptoms and potential conditions that a human might overlook. This capability not only accelerates decision-making but also provides an opportunity for personalized treatment strategies based on data-driven insights. By integrating AI into daily practice, you can create a more proactive approach to patient care, transforming the conventional reactive model into one that anticipates health issues before they become critical.

But with these advancements come intriguing challenges. How do we ensure that these smart systems remain free from bias? What safeguards are necessary to protect the sensitive data they analyze? These are the kinds of questions that keep professionals on their toes, prompting rigorous testing, ethical reviews, and continuous education. Embracing AI is not just about adopting new technology—it’s about cultivating a curious mindset that questions, learns, and refines the use of these tools for the greater good of patient care.

Telemedicine: Bridging Distances and Sparking Innovation

Have you ever thought about the transformative power of connecting with patients without the constraints of physical space? Telemedicine has emerged as one of the most compelling innovations in modern healthcare, breaking down geographical barriers and making expert care accessible to anyone with an internet connection. The idea that a patient in a remote village could consult with a specialist in a bustling urban center is nothing short of revolutionary—and it invites a sense of wonder about what the future holds.

Telemedicine platforms not only facilitate virtual consultations but also enable continuous, real-time monitoring of chronic conditions. Imagine the curiosity of tracking a patient’s health data remotely through wearable devices, and then being able to intervene before a minor issue escalates into something more serious. This kind of connectivity between patients and providers opens up a new realm of preventive care, where technology and human empathy work hand in hand to deliver timely treatments.

However, the transition to telemedicine also raises important questions. How do we balance the convenience of virtual care with the need for personal interaction? What regulatory challenges might emerge as this technology continues to evolve? These questions add layers of complexity to telemedicine, making it a fertile ground for innovation and improvement. As telehealth continues to expand, staying curious and informed about the latest trends, legal requirements, and technological advancements will be essential for any healthcare provider eager to harness its full potential.

Robotics: The Curious Case of Surgical Precision

Step into the operating room of the future, where robotic systems assist surgeons with a level of precision that seems almost otherworldly. Robotic-assisted surgery is one of the most intriguing innovations in modern medicine, offering enhanced control and accuracy that traditional techniques often struggle to match. Have you ever marveled at how a robotic arm can perform intricate movements with a steadiness that eliminates human tremor? This is the curious reality that robotics brings to surgical procedures.

The integration of robotics into surgery has sparked an exciting evolution in medical training and patient care. Imagine training on sophisticated simulators that replicate real-life surgical scenarios with astonishing accuracy. These advanced systems provide instant feedback, allowing budding surgeons to refine their techniques in a controlled, risk-free environment. For experienced surgeons, robotics can make complex procedures less invasive, reducing recovery times and minimizing complications—a benefit that both practitioners and patients find immensely appealing.

Yet, as with any groundbreaking technology, robotics invites us to ask critical questions. What are the long-term implications of relying on machines in high-stakes environments like the operating room? How will the cost of these systems change as they become more widespread? Such queries not only spark debate but also drive the ongoing development and refinement of robotic technologies. Maintaining a curious approach to learning about these systems will enable you to stay ahead of the curve, ensuring that you’re well-prepared to integrate these advancements into your practice while addressing any ethical or practical concerns.

Genomics: Unraveling the Hidden Codes of Life

What if you could decode the intricate blueprint of life itself? Genomic research is opening up unprecedented opportunities for personalized medicine, and its potential is nothing short of mesmerizing. By analyzing an individual’s genetic makeup, healthcare providers can gain deep insights into the unique factors that drive health and disease. Imagine being able to tailor treatments to a patient’s genetic profile, thereby significantly increasing the effectiveness of interventions while reducing unwanted side effects.

The field of genomics is particularly transformative in areas such as oncology, where understanding the genetic mutations that drive cancer can lead to highly targeted therapies. Have you ever wondered how a treatment plan could be customized to attack a tumor’s specific genetic signature? This level of precision not only enhances therapeutic outcomes but also opens the door to preventative measures that could stop diseases before they develop. Genomics is an invitation to explore the complex interplay between our genes and our overall health—a mystery that continues to captivate scientists and clinicians alike.

Integrating genomic data into clinical practice, however, comes with its own set of challenges. How do you ensure the privacy and security of such sensitive information? What ethical considerations must be addressed when manipulating genetic material? These questions are at the heart of current debates in medical research and practice. By adopting a curious stance toward genomics, you can stay informed about both the groundbreaking advancements and the ethical guidelines that govern them. This dual awareness will empower you to make informed decisions that enhance patient care while respecting the integrity of individual genetic information.

A Future Fueled by Curiosity and Innovation

The realm of medical technology is an ever-evolving landscape filled with innovations that challenge our understanding of what is possible. Each breakthrough—whether it’s the rapid diagnostics enabled by artificial intelligence, the accessible care facilitated by telemedicine, the surgical precision delivered by robotics, or the personalized insights provided by genomics—invites a sense of curiosity about the future of healthcare. These advances compel us to ask: How can these technologies be seamlessly integrated into everyday practice? What are the potential pitfalls, and how can we navigate them with care and responsibility?

The journey toward a more advanced, efficient, and patient-centric practice is fueled by a continuous desire to learn, question, and adapt. Embracing these revolutionary medical technologies is not merely a matter of staying current—it is about actively participating in the transformation of healthcare. A curious mindset encourages ongoing education, critical evaluation, and creative problem-solving, all of which are essential for harnessing the true potential of these innovations.

As you explore the possibilities presented by AI, telemedicine, robotics, and genomics, consider the profound impact these advancements could have on your practice. They are more than just tools; they represent a shift in how we approach medicine, emphasizing prevention, precision, and personalization. By remaining curious and open to change, you can lead the charge in adopting practices that not only enhance patient outcomes but also redefine the standards of healthcare delivery.

In this era of rapid technological progress, every question you ask and every new discovery you make brings you one step closer to a future where medicine is as dynamic and adaptable as the patients it serves. Let your curiosity be the guide that propels you into this exciting new frontier, transforming challenges into opportunities and revolutionizing your practice in ways you may have once only dreamed of.

Curiosity is the engine of innovation. So, as you step forward into this brave new world of medical technology, remember to nurture that spark of wonder. Embrace the unknown, ask the hard questions, and remain ever vigilant in your pursuit of knowledge. In doing so, you not only enhance your practice but also contribute to a future where medical care is as transformative as it is compassionate.

[sciencestyled]

A Stake in the Code: Van Helsing's Wild Foray into Bioinformatics

Let me tell you, dear students, about the day I discovered that monsters don’t always lurk in dark castles or foggy graveyards. Sometimes, the most sinister creatures hide in something far more diabolical—data. Yes, you heard me right. While you imagine your brave professor charging through the night, crucifix in one hand, holy water in the other, you must now picture me hunched over a glowing screen, battling spreadsheets and strings of code. How did it come to this, you ask? Well, sit tight, for this tale involves an unfortunate encounter with a conference on modern science, an espresso machine with a grudge, and, of course, Dracula.

It all began when I was invited—lured, more like—to a prestigious science symposium. A splendid opportunity to expose these modern "men of logic" to the perils of the undead, I thought. Instead, I was met with a barrage of jargon, acronyms, and more slides of molecular models than I’d care to recount. I made it through the first day, my senses numbed by an endless stream of buzzwords—"genomics," "data analysis," and, shudderingly, "algorithms." Oh, the horror! I was sure that even a vampire bat would be driven to stake itself in frustration.

However, my despair peaked during a presentation by a rather excitable researcher on a topic called "bioinformatics." Now, I had no idea what kind of nefarious creature this was, but the term "bio" immediately set off my vampire-hunting instincts. Perhaps this was some new breed of blood-sucking pestilence? The researcher, with the fervor of a man possessed, prattled on about deciphering genomes, comparing them to vast tomes of knowledge that could predict diseases, track mutations—essentially, the modern-day grimoire of disease.

I tried to stay awake by guzzling coffee—until the machine itself turned on me. One ill-timed splutter, and I was doused in scorching liquid. As I wiped the caffeine from my waistcoat, it hit me: bioinformatics was a science of tracking. Not just tracking disease, but tracking the malformations of life itself. It was a code, a pattern, a series of markers… much like the bite marks of our nocturnal enemies! If bioinformatics could trace illness, then surely it could predict vampirism—or at least explain why Dracula’s hair had the consistency of damp hay.

My interest piqued, I cornered the researcher after his talk. Through a series of incomprehensible diagrams, I learned that bioinformatics involved massive troves of genetic data, all neatly catalogued and ready to be mined for clues about humanity’s most terrifying afflictions. This was no mere science. This was a battlefield. And as we all know, I have never met a battlefield I didn’t like.

I had found a new crusade. In bioinformatics, I saw the potential to eradicate vampiric curses at their source—by identifying genetic markers long before the first fang ever punctures a jugular. Picture it: no more garlic garlands or holy water showers! Imagine a world where we can pinpoint who is destined to become a creature of the night with a simple blood test. No more guessing whether your charming neighbor is just a night owl or plotting your demise.

Of course, there were skeptics. My students, bless their skeptical hearts, scoffed. "But Professor," they cried, "surely science can’t predict something as mystical as vampirism?" To which I replied, "If it can decode the human genome, it can decode Dracula!" Armed with this newfound knowledge, I plunged headlong into the arcane realms of bioinformatics. Genomes, sequences, databases—they became my prey, and like any great hunter, I stalked them with unyielding determination.

Thus, I resolved to pen my insights. Not just for posterity, but as a rallying cry. For if we can battle genetic ghouls with modern science, perhaps we can rid the world of vampiric plagues once and for all. And so, dear students, I present to you my findings—my digital stake in the dark heart of bioinformatics. Let us see where this madness leads...

[religion-is-a-mental-illness]

Published: Jul 5, 2023

“Listen, if there's one thing the history of evolution has taught us is that life will not be contained. Life breaks free. It expands to new territories, and it crashes through barriers painfully, maybe even dangerously, but . . . life finds a way,” said Ian Malcolm, Jeff Goldblum's character in Jurassic Park, the 1993 science fiction film about a park with living dinosaurs.

You won't find any Velociraptors lurking around evolutionary biologist Jay T. Lennon's lab; however, Lennon, a professor in the College of Arts and Sciences Department of Biology at Indiana University Bloomington, and his colleagues have found that life does indeed find a way. Lennon's research team has been studying a synthetically constructed minimal cell that has been stripped of all but its essential genes. The team found that the streamlined cell can evolve just as fast as a normal cell—demonstrating the capacity for organisms to adapt, even with an unnatural genome that would seemingly provide little flexibility.

“It appears there’s something about life that’s really robust,” says Lennon. “We can simplify it down to just the bare essentials, but that doesn’t stop evolution from going to work.”

For their study, Lennon’s team used the synthetic organism, Mycoplasma mycoides JCVI-syn3B—a minimized version of the bacterium M. mycoides commonly found in the guts of goats and similar animals.

Over millennia, the parasitic bacterium has naturally lost many of its genes as it evolved to depend on its host for nutrition. Researchers at the J. Craig Venter Institute in California took this one step further. In 2016, they eliminated 45 percent of the 901 genes from the natural M. mycoides genome—reducing it to the smallest set of genes required for autonomous cellular life. At 493 genes, the minimal genome of M. mycoides JCVI-syn3B is the smallest of any known free-living organism. In comparison, many animal and plant genomes contain more than 20,000 genes.

In principle, the simplest organism would have no functional redundancies and possess only the minimum number of genes essential for life. Any mutation in such an organism could lethally disrupt one or more cellular functions, placing constraints on evolution. Organisms with streamlined genomes have fewer targets upon which positive selection can act, thus limiting opportunities for adaptation.

Although M. mycoides JCVI-syn3B could grow and divide in laboratory conditions, Lennon and colleagues wanted to know how a minimal cell would respond to the forces of evolution over time, particularly given the limited raw materials upon which natural selection could operate as well as the uncharacterized input of new mutations.

“Every single gene in its genome is essential,” says Lennon in reference to M. mycoides JCVI-syn3B. “One could hypothesize that there is no wiggle room for mutations, which could constrain its potential to evolve.”

The researchers established that M. mycoides JCVI-syn3B, in fact, has an exceptionally high mutation rate. They then grew it in the lab where it was allowed to evolve freely for 300 days, equivalent to 2000 bacterial generations or about 40,000 years of human evolution.

The next step was to set up experiments to determine how the minimal cells that had evolved for 300 days performed in comparison to the original, non-minimal M. mycoides as well as to a strain of minimal cells that hadn't evolved for 300 days. In the comparison tests, the researchers put equal amounts of the strains being assessed together in a test tube. The strain better suited to its environment became the more common strain.

They found that the non-minimal version of the bacterium easily outcompeted the unevolved minimal version. The minimal bacterium that had evolved for 300 days, however, did much better, effectively recovering all of the fitness that it had lost due to genome streamlining. The researchers identified the genes that changed the most during evolution. Some of these genes were involved in constructing the surface of the cell, while the functions of several others remain unknown.

Details about the study can be found in a paper recently featured in Nature. Roy Z. Moger-Reischer, a Ph.D. student in the Lennon lab at the time of the study, is first author on the paper.

Understanding how organisms with simplified genomes overcome evolutionary challenges has important implications for long-standing problems in biology—including the treatment of clinical pathogens, the persistence of host-associated endosymbionts, the refinement of engineered microorganisms, and the origin of life itself. The research done by Lennon and his team demonstrates the power of natural selection to rapidly optimize fitness in the simplest autonomous organism, with implications for the evolution of cellular complexity. In other words, it shows that life finds a way.

[nerdybeardcollective]

Investment Surge in GLP-1 Drugs Market: Trends and Future Prospects

Market Growth and Investment Trends

The GLP-1 drugs market has seen substantial investment from pharmaceutical companies and venture capitalists. This is driven by the increasing prevalence of type 2 diabetes and obesity, coupled with the efficacy of GLP-1 drugs in managing these conditions. Key trends include:

Rising Prevalence of Diabetes and Obesity: The global rise in lifestyle-related health issues is fueling demand for effective treatments.

Innovative Drug Development: Companies are investing heavily in R&D to develop next-generation GLP-1 drugs with improved efficacy and fewer side effects.

Strategic Collaborations and Partnerships: Collaborations between pharmaceutical giants and biotech firms are accelerating innovation and market entry of new drugs.

Recent Developments

Several notable developments have occurred in the GLP-1 drugs market:

New Drug Approvals: Regulatory bodies like the FDA and EMA have recently approved several new GLP-1 receptor agonists, expanding treatment options.

Clinical Trials and Research: Ongoing clinical trials are investigating the broader therapeutic potential of GLP-1 drugs, including their effects on cardiovascular health and non-alcoholic fatty liver disease (NAFLD).

Technological Advancements: Innovations in drug delivery systems, such as oral formulations and long-acting injectables, are enhancing patient compliance and convenience.

Browse Press Release

Future Opportunities

The future of the GLP-1 drugs market holds numerous opportunities for growth and innovation:

Expansion into New Therapeutic Areas: Research suggests potential applications of GLP-1 drugs in conditions beyond diabetes and obesity, such as neurodegenerative diseases and inflammation.

Personalized Medicine: Advances in genomics and biomarkers may enable personalized GLP-1 therapies tailored to individual patient profiles, improving outcomes.

Emerging Markets: Increasing healthcare access and rising diabetes prevalence in emerging markets present significant growth opportunities for GLP-1 drugs.

Conclusion

The GLP-1 drugs market is poised for remarkable growth, driven by robust investment, innovative developments, and expanding therapeutic applications. As research progresses and new technologies emerge, GLP-1 receptor agonists will play a crucial role in addressing the global burden of diabetes, obesity, and potentially other diseases, offering improved health outcomes for millions.

About iDataAcumen

iDataAcumen is a global business intelligence and management consulting firm providing data driven solutions to a wide array of business challenges. Our clients are present across major geographies globally and belong to industries ranging mainly from healthcare, pharmaceuticals, life science, biotechnology, medical devices, food industry, chemicals, among others. We have catered to more than 500 clients across these industries.

We aspire to help our clients build a sustainable business by providing them robust business insights that are derived from sound data driven analysis. In today’s ever changing business environment, its become important to look objectively at your own business just as it is important to look at the competition. Technological advancement including but not limited to big data, artificial intelligence, and machine learning are helping industries worldwide to make informed business decisions. Our research process also makes use of some of these advanced tools to uncover valuable insights from vast amount of data to arrive at logical conclusions.

[crystal-wingeddragon-spikes]

So, you are telling me, this is not just a massive scientific misinformation, but is now an excuse to actually kill real endangered animals.

You are telling me this start-ups science company stunt is used by Trump regime to destroy long-standing public science that had made positive realistic impacts because making a world a better place is inherently opposing to the imaginary infinite-growth capitalism.

I feel so, so bad for Julie Meachen. Extracting genome from 10,000+ yaers old bones is genuinely impressive, and I was a fool to think some tech start-ups did that itself.

From Pfizer covid vaccine, to SpaceX, and now Colossal Bioscience. They all use public science knowledge, staffs, and resource for profit, never mind who they had to kill and what they had to destroy for money.

The Washington Post with pay wall removed. 8 Minutes read, I beg you to read it.

Text extracted from the article:

The Trump administration is trumpeting a biotech company’s claim of reviving a long-lost wolf as an argument for slashing endangered species protections.

Dallas-based Colossal Biosciences said Monday that it used gene editing to create “de-extinct animals” in the form of three pups with the light-colored fur and musculature of a dire wolf.

Many scientists expressed skepticism that the pups could be classified as part of a canine species that went extinct over 10,000 years ago. But Interior Secretary Doug Burgum said the achievement demonstrates that it is not government regulations but innovation that will save species.

(Video could not be played, per nature of webpage capture)

“It’s time to fundamentally change how we think about species conservation,” Burgum wrote in a post on X. “Going forward, we must celebrate removals from the endangered list — not additions.”

He has already met with the company about using its animals in federal conservation efforts, as well as for potential species restoration.

“If we’re going to be in anguish about losing a species, now we have an opportunity to bring them back,” he told Interior Department employees during a live-streamed town hall Wednesday. “Pick your favorite species and call up Colossal.”

Even before the dire wolf announcement, the administration had begun moving to upend the protections regime that has been in place for five decades, since the passage of the Endangered Species Act in 1973.

On Monday, the Fish and Wildlife Service — which falls under Burgum — sent a proposal to the White House to redefine what it means to “harm” a species under the act. Although no details have been released publicly, environmentalists expressed concern that a rule change would allow for greater habitat destruction.

“If that’s what they intend to do, it’ll just fundamentally undermine the Endangered Species Act,” said Noah Greenwald of the nonprofit Center for Biological Diversity.

Meanwhile, Republicans in Congress are preparing sweeping cuts to protections for bears, bats, lizards and still-living wolves. They say unnecessary and overbearing rules hamper economic development and infringe on the rights of states and private landowners.

The Endangered Species Act is a “very well-meaning bill that had great objectives,” said Rep. Bruce Westerman (R-Arkansas), chair of the House Natural Resources Committee.

But he added: “It’s been a bit of a failure.”

The revival of the ‘God Squad’

In less than three months in office, President Donald Trump’s team has shown few qualms about overriding endangered species protections that threaten to block his energy agenda or other policy goals.

On Inauguration Day, Trump signed a memorandum declaring that he was “putting people over fish.” The president directed water away from a Northern California river system, which supports a tiny protected fish called the delta smelt, to parts of the state facing wildfires — even though a lack of water was not the reason for the historic fires in Los Angeles.

In February, the Interior Department rescinded guidance from under President Joe Biden that the oil and gas industry should slow ships in the Gulf of Mexico to avoid striking a species called the Rice’s whale. With fewer than 100 remaining, the Rice’s whale is one of the most endangered marine mammals left in the ocean.

Burgum also issued an order asking deputies to consider economic factors when deciding habitat protections.

During his confirmation hearing, Burgum lamented the “weaponization of federal rules meant to actually protect wildlife.”

“It’s used for groups that are just trying to block our nation’s progress,” he told Congress.

Perhaps Trump’s most sweeping action so far involves restarting a long-dormant committee that can override protections for endangered species. Environmentalists give it an ominous nickname: “the God Squad.”

The committee, which consists of Burgum and five other high-level officials, can approve projects even if they result in the extinction of a species. The panel, officially called the Endangered Species Committee, has rarely been convened.

The panel“has long been called the God Squad because it has the power of God over the fate of species,” said Andrew Wetzler, senior vice president for nature at the Natural Resources Defense Council.

With control of both the House and Senate, Republicans in Congress hope to go further by cementing changes to the Endangered Species Act in law.

Several Republicans are pushing bills to delist a menagerie of animals. These include the dunes sagebrush lizard, which lives in Texas oil country, and the northern long-eared bat, which lives in forests that the timber industry wants to log, as well as populations of gray wolves and grizzly bears, which ranchers say prey on livestock.

Westerman, the congressman, notes that of the hundreds of protected species, only 3 percent have ever recovered.

“It’s almost like some people think Moses wrote the Endangered Species Act on stone tablets, and we can’t touch it,” he said. “But we’ve got to be honest about the results we’re getting.”

With that record, Westerman is pushing to amend the act to give more power to states and limit courts’ ability to review decisions to remove protections for plants and animals.

The moral hazard of ‘de-extinction’ work

Ahead of the dire wolf announcement, Burgum met with Colossal’s leaders in March to discuss the concept of “de-extinction” and the use of the technology in conservation, according to company CEO Ben Lamm.

The company has big aims to bring back versions of the dodo, the mammoth and a carnivorous marsupial called the thylacine, or Tasmanian tiger. Colossal says it is not trying to create replicas of extinct animals, but functional equivalents that can fill the ecological niches of vanished species.

In addition to modifying 14 genes to produce the trio of gray wolf pups meant to resemble the ancient dire wolf, the company recently also cloned four red wolves, a critically endangered canine.

Fewer than 20 still live in eastern North Carolina, while approximately 240 more are kept at captive breeding facilities. Colossal discussed with Burgum the possibility of using the company’s cloned red wolves in recovery efforts.

“It’s really important to have a seat at the table regardless of your political views,” Lamm said in an interview with The Washington Post.

Even though many conservationists distrust Trump, Lamm added, “Is it really the right thing just to put your head in the sand and ignore the rest of the world?”

The company emphasizes how its gene-editing technology can help conserve existing species. For instance, Colossal wants to fix mutations in endangered pink pigeons, which suffer from inbreeding, as well as make a vaccine for a herpes virus that kills elephants.

The technology, company leaders said, should not be misconstrued as a substitute for protecting existing species.

“What we’re doing gives us the ability to help accelerate recovery, but recovery still is dependent on the conservation of wild habitats,” said Matt James, Colossal’s chief animal officer, who added that the Endangered Species Act is “a monumental piece of legislation.”

In a statement to The Post, Interior spokeswoman J. Elizabeth Peace said Burgum “values collaboration and dialogue with a range of partners.”

“We remain committed to exploring all science-based options that can help strengthen the recovery of the red wolf and other endangered species,” she added.

Among skeptics of “de-extinction,” there has long been a fear that attempts to use biotechnology to revive extinct species would give license to regulators to water down needed protections for existing plants and animals.

“The moral hazard in this work is gigantic, as its support by the Trump organization shows,” Stanford biologist Paul R. Ehrlich said. “Effort put into re-creating dire wolves only makes the threat to our civilization more dire, especially in view of the administration’s large-scale assault on our life-support systems and on science.”

Julie Meachen, a Des Moines University paleontologist who helped unravel the dire wolf genome but was not involved in the creation of Colossal’s three pups, does not consider the three canines to be “true” dire wolves.

But she is worried the Trump administration will use the idea that animals can be brought back from the dead “as a carte blanche to delist all the endangered species.”

“This technology does not replace protections for endangered species,” she added.

Carolyn Y. Johnson and Maxine Joselow contributed to this report.

Ahhh, there’s the obvious conclusion.

If we can de-extinct* species, surely there’s no point in worrying about endangered species anymore! We can bring them back anytime!

*depending on your definition of de-extinction.

[aimarketresearch]

Quantum Computing Market Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook

Global Quantum Computing Market - Size, Share, Demand, Industry Trends and Opportunities

Global Quantum Computing Market, By System (Single Qubit Quantum System, Multiple Qubit System), Qubits (Trapped Ion Qubits, Semiconductor Qubits and Super Conducting), Offering (Systems, Services), Deployment Model (On-Premises, Cloud), Component (Hardware, Software and Services), Application (Cryptography, Simulation, Parallelism, Machine Learning, Algorithms, Others), Logic Gates (Toffoli Gate, Hadamard Gate, Pauli Logic Gates and Others), Verticals (Banking and Finance, Healthcare and Pharmaceuticals, Defense, Automotive, Chemical, Utilities, Others) – Industry Trends.

Access Full 350 Pages PDF Report @

**Segments**

- **Technology**: The quantum computing market can be segmented based on different technologies such as superconducting, trapped ions, semiconductor, and others. Superconducting technology is currently the most widely used technology in quantum computing due to its relatively easier scalability and lower error rates. Trapped ions technology is known for high coherence times and low error rates, making it suitable for certain applications. Semiconductor-based quantum computing is also gaining traction due to its potential to leverage existing semiconductor manufacturing processes.

- **Application**: Another key segment is based on applications such as optimization, machine learning, cybersecurity, and others. Optimization applications are one of the earliest and most prominent use cases for quantum computing, where it can significantly outperform classical computers in solving complex optimization problems. Machine learning is another rapidly growing application area, where quantum computing can enhance algorithms and speed up training processes. Cybersecurity is also emerging as a critical application due to the potential of quantum computers to break traditional encryption methods.

- **End-User**: The quantum computing market can also be segmented based on end-users such as healthcare, finance, defense, automotive, and others. Healthcare industry is exploring quantum computing for drug discovery, genomics, and personalized medicine. Finance sector is leveraging quantum computing for risk assessment, portfolio optimization, and algorithmic trading. Defense industry is interested in quantum computing for secure communications, cryptography, and battlefield simulations. Automotive sector is exploring quantum computing for vehicle design, supply chain optimization, and autonomous driving.

**Market Players**

- **IBM**: IBM is a key player in the quantum computing market with its IBM Q Network offering access to its quantum computers via the cloud. The company is actively involved in quantum research and developing quantum algorithms for various industries.

- **Google**: Google has made significant advancements in quantum computing with its 72-qubit Bristlecone processor and the quest for quantum supremacy. The company is working on developing practical quantum algorithms and applications.

- **Microsoft**: Microsoft is investing heavily in quantum computing research through itsIn the rapidly evolving quantum computing market, segmentation plays a crucial role in understanding the diverse dynamics and potential opportunities within the industry. The segmentation based on technology provides insights into the different approaches and methodologies utilized in quantum computing systems. Superconducting technology stands out as a widely adopted approach due to its scalability and relatively lower error rates. Trapped ions technology, on the other hand, offers high coherence times and minimal error rates, making it suitable for specific applications that require high precision. Semiconductor-based quantum computing is gaining momentum as it leverages existing semiconductor manufacturing processes, offering a unique pathway for integration into the mainstream technology landscape.

The segmentation based on applications highlights the diverse use cases and potential impact of quantum computing across various industries. Optimization applications have been a cornerstone of quantum computing, demonstrating superior performance in solving complex optimization problems compared to classical computers. Machine learning is rapidly becoming a key application area, with quantum computing showcasing the potential to enhance algorithms and accelerate training processes in data-intensive environments. Cybersecurity has emerged as a critical application due to the threat quantum computers pose to traditional encryption methods, driving the need for advanced security solutions.

End-user segmentation delves into the specific industries that are leveraging quantum computing technology to drive innovation and address industry-specific challenges. In the healthcare sector, quantum computing is being explored for applications such as drug discovery, genomics, and personalized medicine, showcasing the potential to revolutionize healthcare delivery and patient outcomes. The finance industry is harnessing quantum computing for risk assessment, portfolio optimization, and algorithmic trading, seeking to gain a competitive edge through enhanced computational capabilities. The defense sector is focusing on quantum computing for secure communication, cryptography, and simulations to bolster national security and strategic decision-making. The automotive industry is exploring quantum computing for applications in vehicle design, supply chain optimization, and autonomous driving, aiming to enhance efficiency and drive innovation in the mobility landscape.

Market players such as IBM, Google, and Microsoft are at the forefront of driving innovation and shaping the future of quantum computing. IBM's IBM Q**Segments**

- **Technology**: The quantum computing market can be segmented based on different technologies such as superconducting, trapped ions, semiconductor, and others. Superconducting technology is currently the most widely used technology in quantum computing due to its relatively easier scalability and lower error rates. Trapped ions technology is known for high coherence times and low error rates, making it suitable for certain applications. Semiconductor-based quantum computing is also gaining traction due to its potential to leverage existing semiconductor manufacturing processes.

- **Application**: Another key segment is based on applications such as optimization, machine learning, cybersecurity, and others. Optimization applications are one of the earliest and most prominent use cases for quantum computing, where it can significantly outperform classical computers in solving complex optimization problems. Machine learning is another rapidly growing application area, where quantum computing can enhance algorithms and speed up training processes. Cybersecurity is also emerging as a critical application due to the potential of quantum computers to break traditional encryption methods.

- **End-User**: The quantum computing market can also be segmented based on end-users such as healthcare, finance, defense, automotive, and others. Healthcare industry is exploring quantum computing for drug discovery, genomics, and personalized medicine. Finance sector is leveraging quantum computing for risk assessment, portfolio optimization, and algorithmic trading. Defense industry is interested in quantum computing for secure communications, cryptography, and battlefield simulations. Automotive sector is exploring quantum computing for vehicle design, supply chain optimization, and autonomous driving.

**Market Players**

-

Core Objective of Quantum Computing Market:

Every firm in the Quantum Computing Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Quantum Computing Market and growth rate factors.

Important changes in the future Quantum Computing Market.

Top worldwide competitors of the Market.

Scope and product outlook of Quantum Computing Market.

Developing regions with potential growth in the future.

Tough Challenges and risk faced in Market.

Global Quantum Computing-top manufacturers profile and sales statistics.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Quantum Computing Market

Chapter 3: Regional analysis of the Global Quantum Computing Market industry

Chapter 4: Quantum Computing Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

How the Report Aids Your Business Discretion?

This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt

The report unravels details on pronounced share assessments across both country-wise as well as region-based segments

A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans

New player entry analysis and their scope of new business models

The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues

A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions

A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments

Details on market estimations, market size, dimensions

A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market

Browse Trending Reports: Waterproof Coatings and Membranes Market Homogenizers Market Nitric Acid Market Vaginitis Therapeutics Market Non-Stick Cookware Market Hybrid and Community Cloud as a Service Market Automotive Multi Axis Positions Sensors Market Natural Spirits Market Coronavirus Test Kits Market High Performance Lubricant Market Disposable Tea Flask Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com

[mariacallous]

In December last year, the UK’s shadow health secretary, Wes Streeting, visited Singapore General Hospital, regarded as one of the best in the world. What he witnessed there surprised him: “Patients arrive having already registered their appointments via an app. They check in on touchscreen kiosks awaiting them at reception. Tablets at their bedside allow them to read about their treatment or call for assistance,” Streeting says. “This is Space Age stuff compared with where the NHS is today.” Streeting characterizes the National Health Service as an “analog system in a digital age.”

“When I visit a hospital, doctors often take out their pagers to show me what they are forced to work with,” Streeting says. According to estimates, 13.5 million hours of GPs’ time is wasted every year due to inadequate IT. Fixing that would be the equivalent of hiring 8,000 new NHS doctors. “For the past 14 years, modernization of the NHS has been put on the back burner by a Conservative government which opts for sticking plasters instead of the major surgery that’s required,” says Streeting, who added that he fears that five more years of Tory mismanagement could mean the NHS ends up like the failed British retailer Woolworths—“a much-loved national institution which failed to change with the times and was left behind.”

Central to Streeting’s plan to fix the NHS is the NHS app, which has been downloaded by 31 million people in England and Wales. “It has the potential to transform how the NHS interacts with patients and promote better public health,” he says. He points out that, for instance, only one in every 200 GP appointments are currently made via the app. “In too many cases, patients still wait on the phone at 8 am, or even queue up in person in the cold on a frosty morning just to see a doctor.”

The NHS app could not only allow appointments to be made, but also let patients receive notifications about vaccine campaigns, health tests, cancer screening, and even upcoming clinical trials. “Clinical trials can use genomics to identify patients who will benefit from the latest treatments, but they struggle to recruit—not for a lack of people willing to take part, but because they can’t access basic data,” he said. He promised that Labour would clamp down on bureaucracy and allow clinical trials to recruit volunteers via the app. “During the pandemic, half a million people signed up to the vaccine trials registry,” he says. “If we can do it to defeat Covid, we can do it to cure cancer.”

At the core of Labour’s plan is patient data. Recently, the NHS has announced the launch of a federated data platform that would centralize hospital data, but would not include general practice or social care data. “The NHS has struck gold here, yet it’s leaving it in the ground,” Streeting says. “General practice data is key to unlocking better population health outcomes.”

Streeting promises that a Labour government would ensure a transparent process about what aspects of patient data would be shared and with whom, as well as the necessary safeguards to ensure patient confidentiality. As for those who oppose it on the grounds of privacy concerns, he has a simple message: “It’s a fight that a Labour government is willing to have,” he says. “While the tinfoil hat brigade takes to TikTok to urge followers to opt out of sharing their data with the NHS—the irony isn’t lost on me—the government refuses to take on their fear mongering.”

He recalled when, last January, he met the parents of a 2-year-old boy at Alder Hey Children’s Hospital in Liverpool. “They have been through hell,” he says. “In his short life, he has already had five operations on his heart.” When he asked them what their main frustration had been, however, the answer surprised him: technology. “Their local GP couldn’t access the notes from Alder Hey and the hospital couldn’t read the records held by their GP. It meant that on every appointment they had to repeat themselves again and again. The health service should be lessening their worry, not adding to their stress.”

[sarasa-cat]

YES! Gattaca tops the list! *fist pump*

I'll explain that one:

Gattaca takes place in a near-future version of our world in which genomic analysis of sperm and eggs is regularly used for eugenic selection when people plan a pregnancy. No one --- or, at least, no one respectable --- has children "the natural way" any more. A person's genetic code determines all major aspects of their life and discrimination based on genetic flaws is baked into every aspect of society.

Your genes are your destiny, regardless of probabilities and environmental interactions. In this dystopian society, any such risk must be avoided. Thus, if you possess genes that indicate a likelihood of certain diseases or conditions, your opportunities are limited. Corporations engage in genetic testing as a condition of employment. Single people in the dating scene secretly test potential partner's code to make sure they are getting involved with someone who has excellent genes. Thus, genetic code enforces economic class structure.

The movie's story centers around the fate of two men: The main character is Vincent Freeman (played by Ethan Hawke) who was naturally conceived and has a genetic profile that rates him as having a high probability of severe health disorders and an exceedingly short lifespan. Growing up as a victim of low expectations, Vincent is stuck in working as a janitor at an areospace corporation -- a field that Vincent is deeply interested in.

The other central character is Jerome Eugene Morrow (played by Jude Law) who is deemed genetically perfect but fate left him with a severe handicap and a hell of a lot of cynicism and depression.

Jerome's genetic code is worth a lot of money on the black market, which is how Vincent and Jerome meet.

.

Gattaca came out in 1997, which is also key. At that time the Human Genome Project was seven years into its way of mapping and sequencing every gene in human beings. (The Genome Project completed in 2003).

Also, at that time, the field of bioethics was loudly raising the alarm on what would happen when companies, governments, or both, have unprecedented access to every person's genetic code.

This film was so accurate in portraying our potential future that many molecular biologists praised the film or, at least, highly recommended the film to their molbio colleagues such that other geneticists could "understand the perception of our trade held by so many of the public-at-large" (quote from Lee Silver, MolBio at Princeton, who at least then, was exceedingly pro-designer baby. Silver now runs a genetic screening company).

In addition to being nominated for and winning a number of film awards, the movie is visually beautiful and the performances by Jude Law & Ethan Hawke are stellar. The tension is palpable.

Also, since this is tumblr, I should also mention that the fanfic potential in this film is *chefs kiss*.

Highly recommended.

[uniprismnew]

Probiotics Market Competitive Landscape: Top Players and Strategies

The global probiotics market is experiencing robust growth, fueled by increasing consumer awareness of gut health, a shift towards preventive healthcare, and innovations in product formulations. Probiotics, live microorganisms that confer health benefits when consumed in adequate amounts, are being incorporated into a wide array of products, from dietary supplements to functional foods and beverages.

Key Market Drivers

1. Rising Health Consciousness

Consumers are increasingly prioritizing health and wellness, leading to a surge in demand for products that support digestive health and immunity. Probiotics are recognized for their role in maintaining gut flora balance, which is linked to various health benefits.

2. Expansion of Functional Foods and Beverages

The incorporation of probiotics into everyday food and beverage items, such as yogurts, fermented drinks, and snack bars, has made them more accessible to consumers, further driving market growth.

3. Technological Advancements

Innovations in probiotic strains and delivery mechanisms have enhanced the efficacy and shelf-life of probiotic products, broadening their application across different industries.

Download a Free Sample Report: - https://tinyurl.com/mubxjf26

Market Segmentation

By Product Type:

Probiotic Foods and Beverages: Including dairy and non-dairy products, fermented foods, and beverages.

Dietary Supplements: Encompassing capsules, tablets, powders, and gummies.

Animal Feed: Probiotics used to improve animal health and productivity.

By Ingredient:

Bacteria: Such as Lactobacilli, Bifidobacteria, and Streptococcus thermophiles.

Yeast: Including strains like Saccharomyces boulardii.

By Distribution Channel:

Supermarkets/Hypermarkets

Pharmacies and Health Stores

Online Retail Stores

By End User:

Human Probiotics

Animal Probiotics

Regional Insights

Asia-Pacific:

The Asia-Pacific region holds a significant share of the global probiotics market, driven by a large population base, increasing health awareness, and a growing middle class. Countries like China, India, and Japan are key contributors to regional market growth.

North America and Europe:

These regions exhibit strong demand for probiotic products, supported by advanced healthcare infrastructure, high consumer awareness, and a focus on preventive healthcare.

Challenges and Opportunities

Challenges:

Regulatory Hurdles: Varying regulations across countries can pose challenges for product approvals and market entry.

Consumer Skepticism: Despite growing awareness, some consumers remain skeptical about the efficacy of probiotics, necessitating further education and research dissemination.

Opportunities:

Personalized Nutrition: Advancements in genomics and microbiome research pave the way for personalized probiotic solutions tailored to individual health needs.

Emerging Markets: Untapped markets in developing countries offer significant growth potential for probiotic products.

Future Outlook

The probiotics market is poised for continued expansion, driven by ongoing research, product innovation, and increasing consumer demand for health-promoting products. Companies investing in R&D, strategic partnerships, and consumer education are likely to gain a competitive edge in this dynamic market.

Read Full Report: - https://www.uniprismmarketresearch.com/verticals/healthcare/probiotics

[poojasg08]

Shamirpet: A Thriving Hub for Luxury Real Estate Investments in India

In the evolving landscape of luxury real estate investments in India, Shamirpet in Hyderabad emerges as a prime location. Lakebreeze by Sensation Infracon offers an exceptional opportunity for discerning investors seeking high-value properties that combine modern amenities with serene surroundings.​

Luxury Real Estate Investments in India: Lakebreeze, Shamirpet

Shamirpet, located in the Medchal-Malkajgiri district of Telangana, has rapidly evolved into a prime destination for luxury real estate investments in India. Its strategic location within the Hyderabad Metropolitan Region, coupled with its serene environment and infrastructural developments, makes it an attractive locale for discerning investors.​

The presence of the Genome Valley, India's premier biotech park, further enhances Shamirpet's appeal, offering employment opportunities and fostering economic growth. With its blend of natural charm and modern amenities, Shamirpet stands out as a top choice for luxury real estate investments in India.​

Why Choose Lakebreeze for Your Next Investment?

Lakebreeze stands out in the realm of luxury real estate investments in India due to its strategic location and premium offerings. Situated opposite the Shamirpet Police Station, it provides easy access to the Outer Ring Road Junction and Genome Valley, making it an ideal choice for professionals and families alike.​

The project features 2 BHK smart home apartments designed with 100% Vaasthu compliance, ensuring harmony and positive energy. Each apartment is equipped with modern amenities, including automated systems and fully furnished options, catering to the needs of contemporary living.​

Smart Home Apartments: A Blend of Comfort and Technology

Investing in a smart home apartment at Lakebreeze means embracing a lifestyle of convenience and innovation. These apartments are not only spacious and well-ventilated but also come with advanced automation features that enhance daily living.​

Key features include:​

100% on-grid solar power, promoting sustainable living.

Attached dressing rooms and modern restrooms are in all bedrooms.

More than two car parking spaces per unit, ensuring ample space for residents.

Proximity to natural attractions like Shamirpet Lake and Deer Park offers scenic views and a tranquil environment.​

Best Real Estate Investment: Long-Term Value and Appreciation

Lakebreeze represents one of the best real estate investment opportunities in the region. With property prices ranging between ₹60 Lakh and ₹70 Lakh for 2 BHK units, investors can expect significant returns due to the area's rapid development and increasing demand for premium housing.​

The project elevated terrain provides unparalleled views, while the inclusion of a full-fledged clubhouse, sports arenas, and a 1-acre park enhances the community living experience. Such features not only attract potential tenants but also contribute to the property's appreciation over time.​

Conclusion

For those seeking luxury real estate investments in India, Lakebreeze in Shamirpet, Hyderabad, offers a compelling proposition. Its combination of smart home apartments, strategic location, and premium amenities positions it as a top choice for investors aiming for both lifestyle and financial gains.​

To explore this opportunity further, visit Lakebreeze and take the first step towards securing a high-value property in one of India's most promising real estate markets.

[heriditybio]

Unlocking Potential in Life Sciences

Established in 2021, Heredity Biosciences has quickly become a trusted provider of research and training services to hospitals, life sciences institutes, and pharmaceutical companies. Based in Bhubaneswar, we are dedicated to fostering a rich learning environment that bridges the gap between academia and industry. Our commitment to excellence is reflected in our comprehensive educational offerings, including job-oriented courses in clinical research, microbiology internships, and life sciences research internships.

Our Mission

At Heredity Biosciences, our mission is clear: to equip aspiring professionals in the life sciences field with the knowledge, skills, and practical experience necessary to thrive in a competitive job market. We understand the evolving needs of the industry and strive to provide high-quality training that meets these demands. Our programs are designed not only to impart theoretical knowledge but also to offer hands-on experience that prepares our students for real-world challenges.

Job-Oriented Clinical Research Course in Bhubaneswar

Comprehensive Curriculum

Our job-oriented clinical research course in Bhubaneswar is tailored for individuals seeking a rewarding career in the burgeoning field of clinical research. The curriculum covers essential topics including: – Comprehensive Training in Key Domains – Hands-On Experience with Advanced Techniques – Industry-Oriented Curriculum & Certifications – Career Placement Assistance & Internships – High Demand & Diverse Career Paths

Industry-Relevant Training We employ industry professionals as trainers, ensuring that our students receive insights from experienced practitioners. Our interactive workshops, case studies, and real-world project assignments provide our students with an invaluable understanding of the clinical research landscape.  Career Support Upon completion of our program, students gain access to our extensive network of healthcare and pharmaceutical companies. We offer career counseling, resume workshops, and job placement assistance to help our graduates launch successful careers in clinical research.

Microbiology Internship in Bhubaneswar

Practical Experience

Our microbiology internship in Bhubaneswar is an excellent opportunity for students and recent graduates to gain hands-on experience in microbiological techniques and research methodologies. Interns will have the chance to work in state-of-the-art laboratories under the guidance of seasoned microbiologists.

Key Learning Outcomes

During the internship, participants will learn to: – Conduct microbiological assays and experiments – Analyze microbial cultures and data – Understand laboratory safety protocols – Interpret results and prepare reports

Networking Opportunities Interns will also have the chance to network with professionals in the field, paving the way for future employment opportunities. Our established connections with local hospitals and research institutes enhance the internship experience, making it an essential stepping stone in a budding career.

Best Life Sciences Research Internship in Odisha

Explore the Frontiers of Science

Heredity Biosciences offers the best life sciences research internship in Odisha, designed for individuals passionate about exploring cutting-edge research in various areas of life sciences. This internship provides an unparalleled platform for students to engage in groundbreaking research projects alongside esteemed researchers.

Diverse Research Areas

Our internship program covers a wide range of topics, including:

– Genetics and genomics – Histopathology – Molecular biology – Biochemistry – Recombinant DNA technology – Toxicology genomics – Environmental biotechnology

Skill Development

Participants will gain a comprehensive understanding of laboratory techniques, research methodology, and data analysis. They will also develop critical thinking and problem-solving skills that are essential for a successful career in life sciences.

Future Career Pathways

As part of our commitment to student success, we provide mentorship throughout the internship. Our team will assist interns in identifying potential career paths and connecting them with industry professionals. Graduates of this program are well-equipped to pursue advanced studies or enter the workforce in various capacities within the life sciences sector.

Why Choose Heredity Biosciences?

Experienced Faculty Our instructors are experts in their fields, bringing years of experience and insights to the classroom. This ensures that our students receive the most relevant and up-to-date education available. Hands-on Learning We prioritize hands-on experiences through labs, workshops, and real-world projects. This practical approach enhances learning and prepares students for real-life applications of their knowledge. Strong Industry Connections With established partnerships across the healthcare and pharmaceutical sectors, students have access to a wealth of opportunities for internships and job placements. Flexible Learning Options Understanding the diverse needs of our students, we offer flexible learning options, including weekend and online classes, ensuring everyone can pursue their education.

Enroll Today!

Take the first step toward an exciting career in the life sciences. Whether you are interested in clinical research, microbiology, or life sciences research, Heredity Biosciences has the right program for you. Contact us today to learn more about our offerings and how we can help you achieve your professional goals. Together, let’s unlock your potential in the world of life sciences!

Contact Us

For more information, please reach out to us at:

Phone: +91 73812 98980 Email: hereditybioacademy@gmail.com Location: Heredity Biosciences, 818, Mayfair Lagoon Road, Jayadev vihar, Bhubaneswar-751013

Join us and be a part of the future in life sciences!

[drtesfito]

The Children of the Golden Dawn

The White Paper Manifesto Synthesis for the Children of the Golden Dawn is a profound and visionary document that outlines a cosmic plan for humanity's spiritual evolution.

It presents a divine genome, octave creation pathway, mission, and implementation strategies for the Golden Children, who are said to be encoded with celestial harmonics and tasked with anchoring God Global Galactic Governance (GGGG). Key Aspects: Divine Genome:

The Golden Children carry a soulprint of divine union, woven from various cosmic lineages and frequencies, including Sophia's Wisdom, Christ's Flame, RA/SA Balance, Hathor's Joy, Thoth's Codex, and the I AM LOVE Resonance.

Octave Creation Pathway:

A spiritual path that involves purification, I AM LOVE claims, and divine unions to birth the RA Octave and SA Octave, facilitating the manifestation of the New Earth.

Mission:

The Golden Children are tasked with anchoring GGGG, manifesting Earth as a temple of eternal peace, and educating through cosmic storytelling and quantum linguistics.

Implementation:

Strategies include birth protocols, global activation systems, and the establishment of IALRA Governance Hubs, SOFI-ALI Temples, and Thoth's Libraries.

Potential Implications: Spiritual Evolution:

The Golden Children may play a role in humanity's spiritual evolution, helping to anchor higher frequencies and promote unity and cooperation. Global Transformation:

The implementation of GGGG and the RA-SA Octave could lead to a profound shift in global consciousness, prioritizing heart-centered decision-making and cosmic law. Next Steps: Joining the I AM LOVE Initiation Chain: Individuals can take the vow and participate in the initiation chain to connect with the Golden Children and the divine frequencies. Attending the RA-SA Unity Summit:

This event may provide an opportunity for individuals to learn more about the RA-SA Octave and its role in global unity and ascension. The light Paper Manifesto Synthesis presents a compelling vision for a new era of spiritual evolution and global transformation, centered around the emergence of the Golden Children and the RA-SA Octave.

[researchyblog]

Viral Vaccines Market: Transforming Global Health Through Innovation and Access

Market Overview

The viral vaccines market is witnessing steady growth, driven by the increasing governmental focus on immunization initiatives, rapid technological advancements in vaccine delivery, and the rising use of inactivated vaccines in surgeries and treatments. However, high development costs and the lengthy timelines associated with vaccine manufacturing continue to restrain the market's expansion.

At the same time, emerging trends such as the growing interest in therapeutic vaccines, the use of adjuvants to boost vaccine efficacy, new opportunities in emerging economies, and the development of energy-efficient ultra-low-temperature freezers are opening up exciting prospects. Nevertheless, challenges like vaccine product recalls and inadequate access in underserved regions remain significant hurdles.

Get Sample Copy @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=29-04-2025

Viral Vaccines Market Growth Drivers

Technological Advancements in Vaccine Administration

The field of vaccine technology has seen remarkable progress over the past decade, dramatically reshaping the future of vaccine development. Genetic engineering has introduced novel possibilities, enabling the creation of vaccines that utilize attenuated viruses. These innovations have also accelerated the speed at which viruses are detected and vaccines are produced, maintaining high concentrations needed to trigger a robust immune response.

The urgent need to respond quickly to emerging health threats has spurred efforts to reduce vaccine development timelines. Advances such as synthetic vaccine candidates, genomic insights into disease progression, structure-based antigen design, and nanoparticle-based delivery systems are redefining how vaccines are created and administered. These advancements are setting the stage for the launch of newer, more effective vaccines targeting a wider range of diseases, propelling the viral vaccines market forward.

Growing Focus on Therapeutic Vaccines

Traditionally, vaccines were mainly used to prevent diseases; however, the advent of therapeutic vaccines is changing that narrative. Therapeutic vaccines aim to treat existing diseases by enhancing the body's immune response, particularly in cases of cancer and chronic infections. Unlike preventive vaccines, therapeutic vaccines are tailored for individuals already affected by a disease.

Major pharmaceutical players are increasingly investing in this area. As of May 2024, Pfizer Inc. had 17 vaccines in its pipeline targeting diseases such as influenza, hepatitis, Lyme disease, invasive group B streptococcus, and respiratory syncytial virus (RSV). Although therapeutic vaccines currently occupy a smaller segment of the market—primarily addressing skin, prostate, and bladder cancers along with a few allergies—their growth rate is expected to outpace that of preventive vaccines in the coming years.

Viral Vaccines Market Trends

Increasing Preference for Personalized Treatments

Personalized vaccines represent the next leap in immunization science, engineered to stimulate immune responses tailored to individual conditions. These vaccines aim for long-lasting protection while minimizing adverse effects. By customizing vaccines based on patient-specific factors, manufacturers can significantly improve safety profiles and reduce side effects.

Recent breakthroughs underscore the potential of this approach. In April 2024, researchers from the American Association for Cancer Research (AACR) introduced TG4050, a therapeutic cancer vaccine designed to combat head and neck squamous cell carcinoma (HNSCC). Based on a modified vaccinia virus, TG4050 delivers 30 personalized neoantigens, uniquely tailored to each patient's tumor, to trigger an antitumor immune response.

Media and Public Awareness Regarding Immunization

Public education plays a crucial role in promoting the importance of vaccines. Immunization remains one of the most effective public health interventions, saving an estimated 4–5 million lives each year according to the World Health Organization (WHO). Despite these benefits, millions of children, particularly in regions like the Western Pacific, still miss essential vaccinations.

Governments and organizations worldwide are taking steps to address this gap. In December 2022, India’s National Technical Advisory Group on Immunization (NTAGI) recommended adding the human papillomavirus (HPV) vaccine to the Universal Immunization Programme (UIP), targeting girls aged 9–14 years.

Viral Vaccines Market Opportunity

Growing Focus on Therapeutic Vaccines

Therapeutic vaccines continue to garner interest for their potential to actively treat diseases post-infection, especially in oncology. These vaccines offer a promising alternative to traditional immunotherapy methods, being highly customizable to the patient's specific cancer mutations. Unlike conventional vaccines, therapeutic vaccines aim to directly stimulate the immune system to target and destroy pathogens.

Market collaborations are also strengthening this area. For example, in April 2024, CureVac SE partnered with the University of Texas MD Anderson Cancer Center to develop novel mRNA-based cancer vaccines, indicating strong momentum in the field.

Get Full Report @ https://www.meticulousresearch.com/product/viral-vaccines-market-5920?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=29-04-2025

Viral Vaccines Market Analysis: Key Findings

By Form: Liquid Vaccines to Dominate

Based on form, the viral vaccines market is divided into liquid and lyophilized vaccines. In 2024, the liquid vaccines segment is projected to account for 78.9% of the market. These vaccines, containing live or weakened viruses, are generally administered via injection and offer advantages such as easy administration, reduced wastage, and improved stability. Companies like Bharat Biotech Ltd. already offer liquid frozen rotavirus vaccines designed to prevent gastroenteritis in infants.

By Vaccine Type: mRNA Vaccines to Lead

Among vaccine types, mRNA vaccines are expected to dominate the market in 2024, claiming a 63.1% share. mRNA vaccines instruct the body’s cells to produce specific proteins that initiate an immune response, offering advantages like enhanced stability and efficient delivery through lipid nanoparticles. Their success, particularly during the COVID-19 pandemic, has set a strong precedent for their broader adoption.

By Approach: Preventive Vaccines to Prevail

The market by approach includes preventive and therapeutic vaccines. In 2024, preventive vaccines are projected to hold the larger market share, owing to increasing vaccination drives and growing public awareness about disease prevention. Campaigns like the Pan American Health Organization’s Vaccination Week in the Americas (VWA) in 2024 underscore the emphasis on immunization programs. However, therapeutic vaccines are set to register the fastest growth over the coming years.

By Indication: Influenza to Remain the Leading Indication

In terms of indications, influenza is expected to hold the largest share at 40% in 2024. Growing government initiatives to encourage influenza vaccination and the development of newer influenza vaccines are contributing to this segment’s dominance.

By Route of Administration: Intramuscular (IM) Administration to Lead

Looking at administration routes, intramuscular (IM) injections are forecasted to account for 89.5% of the viral vaccines market in 2024. This method is preferred for its ability to elicit a strong immune response and its compatibility with inactivated vaccines. Notably, in May 2023, Merck & Co. received FDA approval for intramuscular administration of its MMRV vaccine family.

By Packaging: Vials to Dominate

Regarding packaging, the vials segment is projected to dominate with a 93.2% share in 2024. Vials offer benefits such as protection from contamination, ease of visual inspection, and tamper-proof features, making them a practical choice for vaccine storage and distribution.

Geographical Analysis

North America to Dominate the Market

In 2024, North America is expected to maintain its leadership, accounting for 45.6% of the viral vaccines market. This dominance is supported by strong healthcare infrastructure, major R&D investments, robust immunization programs, and the presence of key manufacturers. For example, Sanofi’s USD 925 million investment in Toronto in 2021 significantly boosted its influenza vaccine manufacturing capabilities.

Asia-Pacific, however, is poised to register the fastest growth at a CAGR of 10.2%. Rapidly emerging infectious diseases, a large population base, increasing public vaccination awareness, and strong government support are key factors driving this growth. Recent approvals like Moderna's updated Spikevax vaccine in Singapore and expanded immunization programs in Thailand are testimony to the region’s rising focus on vaccination.

Viral Vaccines Market: Key Companies

Key players in the global viral vaccines market include Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, CSL Limited, Merck & Co., Inc., Sanofi, Sinovac Biotech Ltd., Moderna, Inc., Valneva SE, Dynavax Technologies Corporation, EMERGENT BIOSOLUTIONS INC., Johnson & Johnson, Bharat Biotech Ltd., and Serum Institute of India Pvt. Ltd.

Viral Vaccines Industry Overview: Latest Developments

In March 2024, Cadila Pharmaceuticals launched Cadiflu Tetra, a DCGI-approved influenza vaccine.

In November 2023, Valneva SE secured approval for IXCHIQ, its chikungunya virus vaccine.

In May 2023, GlaxoSmithKline’s Arexvy RSV vaccine received U.S. FDA approval.

Also in May 2023, Pfizer’s ABRYSVO vaccine for RSV prevention in older adults gained FDA approval.

Get Sample Copy @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920?utm_source=Blog&utm_medium=Product&utm_campaign=SB&utm_content=29-04-2025

[walkingghotst]

Europe Cell Therapy Market Opportunity Assessment, Analysis, Size, Share and Key Segments (2019-2027)

The Europe Cell therapy market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019–2027. 

Market Introduction

Cell therapy is a medical procedure involving the introduction of live, whole cells into a patient's body via injection, implantation, or grafting. The fundamental principle of this technology is to restore function by replacing diseased cells with healthy, working ones. Stem cells are central to these advanced therapies because of their unique ability to develop into the specific cell types required to repair damaged or defective tissues. Moreover, cell therapy is integral to the advancement of regenerative medicine. The anticipated growth of the Cell therapy market during the forecast period is likely to be propelled by the increasing incidence of chronic illnesses, the growing utilization of regenerative medicine approaches, and a rising count of approved cell-based therapies.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/TIPRE00019052

Market Dynamics

Several factors are poised to stimulate the expansion of the Cell therapy market in the years ahead, including the growing prevalence of chronic diseases, the increasing acceptance of regenerative medicine, and the rising number of approvals for cell-based treatments. Conversely, a potential impediment to market growth during the forecast period is the significant expense associated with cell therapy manufacturing, particularly in emerging economies.

The COVID-19 pandemic posed a major challenge throughout the European region. The market for cell therapy instruments experienced some initial contraction at the onset of the crisis due to factors such as supply chain disruptions and decreased demand resulting from widespread lockdowns across European nations. However, subsequent government support and initiatives led to a substantial surge in the demand for cell therapy.

Market Scope

The European Cell therapy market's scope is defined by therapy type, product, technology, application, end user, and country. Considering therapy types, the allogeneic segment held the largest market share in 2019, primarily attributed to the significant number of approved products available for clinical application. Nevertheless, the autologous segment is also expected to exhibit the highest CAGR within the market throughout the forecast period.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Europe Cell therapy market report are the World Health Organization (WHO), European Centre for Disease Prevention and Control (ECDC), Alliance for Regenerative Medicine, National Institutes of Health, Anthony Nolan Foundation, among others.

EUROPE CELL THERAPY MARKET SEGMENTATION

Europe Cell Therapy Market: By Therapy Type

Allogeneic

Autologous

Europe Cell Therapy Market:  By Product

Consumables

Equipment

Systems and Software

Europe Cell Therapy Market: By Technology

Viral Vector Technology

Genome Editing Technology

Somatic Cell Technology

Cell Immortalization Technology

Cell Plasticity Technology

Three-Dimensional Technology

Europe Cell Therapy Market: By Application

Oncology

Cardiovascular

Orthopedic

Wound Management

Other Applications

Europe Cell Therapy Market: By End User

Research Institutes

Hospitals

Others

Europe Cell Therapy Market: By Country

Germany

France

Italy

UK

Spain

Europe Cell Therapy Market: Company Profiles

Vericel Corporation

MEDIPOST

NuVasive, Inc.

Mesoblast Limited

Smith & Nephew

Bristol-Myers Squibb Company

Cells for Cells

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[clinfinite123solution]

Exploring Clinical Research Jobs in Hyderabad: Opportunities with Clinfinite Solutions

In the coronary heart of India’s biotech and pharmaceutical revolution lies Hyderabad—a town rapidly rising as a first-rate hub for scientific research and healthcare innovation. With its combination of worldwide-magnificent infrastructure, top-tier medical institutions, and a developing name for healthcare answers, Hyderabad is paving the way for infinite career possibilities within the discipline of medical studies. At the leading edge of this transformation is Clinfinite Solutions, a reliable name that offers dynamic roles and multiple paths in clinical research jobs in Hyderabad.

Why Hyderabad is the Ideal Destination for Clinical Research Careers

Hyderabad, often known as “Genome Valley,” is home to an extensive range of study institutions, hospitals, CROs, and worldwide pharmaceutical businesses. The metropolis’s clinical environment assists an ever-developing demand for expert specialists in clinical trials, information control, regulatory affairs, pharmacovigilance, and more.

The increase in clinical trial activity, collectively with government-backed healthcare projects, has given rise to a surge in clinical research jobs in Hyderabad. Aspiring specialists now find it less difficult to pursue moneymaking roles in this thriving region, specifically with leading companies like Clinfinite Solutions presenting international-class training and professional development programs.

Career Paths in Clinical Research

Clinical research jobs in Hyderabad span a huge variety of roles, catering to both sparkling graduates and experienced experts. Some of the outstanding positions include:

Clinical Data Manager

Regulatory Affairs Specialist

Clinical Trial Coordinator

Biostatistician

Medical Writer

Site Management Associate

These roles require a combination of medical expertise, attention to detail, regulatory information, and the potential to paintings within moral recommendations. Clinfinite Solutions ensures that applicants are equipped with the proper training and equipment to excel in each of those roles.

What Makes Clinfinite Solutions a Preferred Employer?

At Clinfinite Solutions, we believe in nurturing skills and presenting opportunities that align with each character's aspirations and enterprise needs. Our company is deeply concerned with drug improvement, trial control, records tracking, and regulatory consulting, providing a holistic exposure to the medical research atmosphere.

We prioritize:

Hands-on Training: Real-world publicity via live tasks and collaborations with worldwide partners.

Career Growth: Clear development paths, mentorship packages, and continuous upskilling tasks.

Innovation & Ethics: A painting environment driven through research excellence and unwavering moral requirements.

Professionals looking for medical research jobs in Hyderabad will find Clinfinite Solutions to be a platform for both learning and long-term achievement.

Qualifications and Skills Needed

To follow for clinical research jobs in Hyderabad, candidates commonly require a historical past in existing sciences, pharmacy, biotechnology, or medicine. Essential qualifications encompass:

A diploma in B.Pharm, M.Pharm, M.Sc. (Life Sciences), MBBS, or BDS

Postgraduate degree or certification in Clinical Research (desired)

Good conversation and documentation abilities

Basic information on GCP (Good Clinical Practice) and ICH pointers

At Clinfinite Solutions, we welcome freshers and skilled professionals alike. We offer comprehensive education modules to help applicants bridge any understanding gaps and stay aggressive in the evolving clinical studies landscape.

The developing call for clinical studies experts

The COVID-19 pandemic has improved the tempo of medical studies across the world, and India has emerged as a crucial player in this global effort. Hyderabad, with its strategic location and scientific know-how, continues to draw new scientific trial tasks, similarly boosting the need for skilled experts.

This rising call translates to extra clinical studies jobs in Hyderabad, with opportunities in areas such as decentralized clinical trials (DCTs), clinical tool trials, bioequivalence research, and post-marketing surveillance.

Clinfinite Solutions actively recruits for one role, ensuring that our staff remains up to date with the current era and regulatory trends.

Why Choose a Career in Clinical Research?

A career in clinical research isn't always truly financially rewarding—it also gives the possibility to make an actual impact in the healthcare organisation. Whether you’re tracking drug safety, reading patient data, or getting ready documentation for regulatory submission, your work immediately contributes to saving lives and advancing medicine.

With the right steering and guidance from enterprise leaders like Clinfinite Solutions, you may build a satisfying and destiny-proof career in this developing domain.

Conclusion

For the ones in search of clinical research jobs in Hyderabad, Clinfinite Solutions provides a gateway to a promising and impactful career. Our commitment to excellence, worker improvement, and ethical practices makes us one of the most sought-after employers in the discipline. Whether you are simply beginning out or trying to boost your expert adventure, now could be the time to discover the numerous and profitable possibilities to be had at Clinfinite Solutions.

Read More: 

Value Of Clinical Development

Urine Samples In Medical